10x Genomics' Products Are Well-Received, But US Spending Weakness Stifles Growth (NASDAQ:TXG)

Core Insights - 10x Genomics (TXG) achieved unexpected profitability in the second quarter, leading to a positive market reaction and an upgrade from a sell to a hold rating [1] Financial Performance - The company reported a surprise profitability in Q2, which was a significant shift from previous performance metrics [1] Analyst Sentiment - The upgrade in rating reflects a growing confidence in the company's potential for future growth and value return to investors [1]